University of Minnesota
Minneapolis, Minnesota, 55414, United States
Location status: Recruiting
NCT Number: NCT05934747
In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP.
Interested in participating?
Request Info18 year–85 year
All sexes
Interventional
Not applicable
Minneapolis, Minnesota, 55414, United States
Location status: Recruiting
In Parkinson's disease (PD) patients undergoing standard-of-care Deep Brain Stimulation (DBS) therapy, to compare the effect on Parkinson's symptoms of two different neurostimulator settings designed to differ from each other as much as possible with respect to how much they activate two different neuroanatomical structures: the axonal pathway from Globus Pallidus (GP) to Pedunculopontine Nucleus (PPN), and the axonal pathway from PPN to GP. In this respect, the present protocol is similar to Protocol STUDY00008644. In fact, that protocol, and this one, cover different Aims of the same NIH-funded project. Protocol STUDY00008644 tested different neurostimulor settings for a few hours in the laboratory only; the present protocol also tests them for two weeks between laboratory testing sessions. This is essential, for several reasons. First, clinically relevant outcome measures, such as ADL (activities of dailly life) and QOL (quality of life) scales require observation for longer than a few hours in the laboratory. Second, DBS effects are not instantaneous, and prolonged observation is required to determine the full effect of neurostimulator settings. Third, we intend, if our hypothesis is confirmed (that activation of the PPN-to-GP pathway is most effective for the postural-instability / gait-disorder (PIGD) complex) to propose a clinical trial of neurostimulator settings designed to maximize activation of this pathway; the present protocol will yield data and experience essential for designing and proposing such a trial.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
MoCA=23+
OR: If MoCA score is 23 or less, UBACC will be performed to ensure capacity to consent. If UBACC results are unclear, the MacCAT-CR will be performed. Failed or unclear MacCAT-CR results will exclude the study candidate.
8.2 Exclusion Criteria:
Deep Brain Stimulation
Time frame: 1 hour and 2 weeks after intiating stimulation
Difference in scores on MDS-UPDRS
Contact information is provided by the study sponsor or research team.
University of Minnesota
Other
Aim 3 Particle Swarm Optimization Postural Instability Gait Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07685873
Basal Ganglia Diseases, Brain Diseases
Hefei, Anhui, China
View Trial DetailsNCT07636720
Basal Ganglia Diseases, Brain Diseases
San Antonio, Texas, United States
View Trial DetailsNCT06350617
Basal Ganglia Diseases, Brain Diseases
Seoul, South Korea
View Trial DetailsNCT06508801
Basal Ganglia Diseases, Brain Diseases
San Antonio, Texas, United States
View Trial Details